Overview

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer

Phase:

PHASE1

Details

Lead Sponsor:

Shanghai Hengrui Pharmaceutical Co., Ltd.

Treatments:

Carboplatin